These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2994377

  • 21. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation- and cyclophosphamide-induced attenuation in antitumor resistance.
    Milas L, McBride WH, Hunter N, Ito H.
    Cancer Res; 1984 Jun; 44(6):2382-6. PubMed ID: 6327014
    [Abstract] [Full Text] [Related]

  • 22. Acute in vivo resistance in high-dose therapy.
    Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E.
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [Abstract] [Full Text] [Related]

  • 23. Amifostine (WR-2721) selective protection against melphalan genotoxicity.
    Buschini A, Anceschi E, Carlo-Stella C, Regazzi E, Rizzoli V, Poli P, Rossi C.
    Leukemia; 2000 Sep; 14(9):1642-51. PubMed ID: 10995012
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
    Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SM, Culo F.
    Br J Cancer; 1980 Oct; 42(4):574-85. PubMed ID: 6254555
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Protection by WR-2721 and WR-151327 against late effects of gamma rays and neutrons.
    Grdina DJ, Garnes BA, Nagy B.
    Adv Space Res; 1992 Oct; 12(2-3):257-63. PubMed ID: 11537016
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Phase I controlled trials of WR-2721 and cyclophosphamide.
    Glick JH, Glover D, Weiler C, Norfleet L, Yuhas J, Kligerman MM.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1777-80. PubMed ID: 6090370
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The role of WR-2721 in radiotherapy and/or chemotherapy.
    Yuhas JM, Spellman JM, Culo F.
    Cancer Clin Trials; 1980 Sep; 3(3):211-6. PubMed ID: 6254681
    [Abstract] [Full Text] [Related]

  • 36. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK, Fahey RC, Dubowy RL, Newton GL, Bernstein ML.
    Cancer Chemother Pharmacol; 1999 Sep; 44(6):498-504. PubMed ID: 10550571
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
    Twentyman PR.
    Br J Cancer; 1981 Jun; 43(6):745-55. PubMed ID: 6264941
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.